Current Report Filing (8-k)
November 21 2019 - 5:03AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
November 20, 2019
Hepion
Pharmaceuticals, Inc.
(Exact name of registrant as specified in
its charter)
|
Delaware
|
|
001-36856
|
|
46-2783806
|
|
(State or other jurisdiction
|
|
(Commission
|
|
IRS Employer
|
|
of incorporation or organization)
|
|
File Number)
|
|
Identification No.)
|
399 Thornall Street, First Floor
Edison, NJ 08837
(Address of principal executive offices)
Registrant’s telephone number, including
area code: (732) 902-4000
(Former name or former address, if changed
since last report)
Securities registered pursuant to Section 12(b) of
the Act:
|
Title of each class:
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered:
|
|
Common Stock
|
|
HEPA
|
|
Nasdaq Capital Market
|
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communication
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging
growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company x
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. x
On
November 20, 2019, Hepion Pharmaceuticals, Inc. issued a press release announcing that CRV431, an anti-fibrotic agent,
prevented the development of liver cirrhosis in a highly aggressive, preclinical model of liver disease. A
copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
Dated: November 20, 2019
|
|
HEPION PHARMACEUTICALS, INC.
|
|
|
|
|
|
|
|
|
|
|
By:
|
/s/ Robert Foster
|
|
|
|
Robert Foster
|
|
|
|
Chief Executive Officer
|
Hepion Pharmaceuticals (NASDAQ:HEPA)
Historical Stock Chart
From Oct 2024 to Nov 2024
Hepion Pharmaceuticals (NASDAQ:HEPA)
Historical Stock Chart
From Nov 2023 to Nov 2024
